Leqvio (Inclisiran) Cost in Nebraska 2026: Prices, Coverage, and Compounding Options

What Is Inclisiran and Why Does It Matter for Nebraska Patients?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 synthesis, reducing circulating LDL cholesterol by approximately 50% with just two injections per year after loading doses. The FDA approved inclisiran on December 22, 2021, for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy [1].

Cardiovascular disease is the leading cause of death in Nebraska. The CDC reports that heart disease accounts for 21.5% of all Nebraska deaths annually [2]. For patients with established atherosclerotic cardiovascular disease (ASCVD) who cannot achieve target LDL-C on statins alone, a therapy requiring only two clinic visits per year for dosing represents a meaningful shift in how adherence problems get addressed.

In the ORION-10 trial (N=1,561), inclisiran 284 mg subcutaneous injection reduced LDL-C by 52.3% from baseline versus a 1.7% reduction with placebo at day 510 (P<0.001) [3]. The companion ORION-11 trial (N=1,617) confirmed a 49.9% LDL-C reduction versus placebo at day 510 (P<0.001) [3]. Both trials ran 18 months and enrolled patients with ASCVD or ASCVD risk equivalents on maximally tolerated statin therapy.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states that for patients with clinical ASCVD who remain above LDL-C 70 mg/dL on maximally tolerated statin therapy, adding a PCSK9 inhibitor or inclisiran is a Class IIa recommendation [4]. That guideline is directly relevant to the thousands of Nebraskans managing post-MI, post-stroke, or peripheral artery disease.

How Much Does Leqvio Cost in Nebraska in 2026?

The manufacturer (Novartis) list price for inclisiran in Nebraska is $540 per month, which translates to roughly $3,240 per six-month dose at retail pharmacies in 2026. Cash-pay patients face this full amount without insurance or manufacturer assistance.

That number, however, is rarely what most patients actually pay. The true out-of-pocket figure depends on insurance tier, prior authorization status, eligibility for manufacturer savings programs, and whether a patient qualifies for compounded inclisiran through a licensed 503A pharmacy.

The American Heart Association notes that LDL-C lowering therapies with proven mortality benefit remain underutilized partly because of cost barriers [5]. Inclisiran's twice-yearly dosing schedule was specifically designed to reduce adherence-related cost burdens, but the acquisition cost itself creates its own barrier for uninsured or underinsured Nebraskans.

Nebraska does not have a state-level pharmaceutical assistance program specifically targeting PCSK9 inhibitors or inclisiran. Patients relying entirely on cash pay at retail pharmacies face the full $540/month equivalent list price [6].

A HealthRX review of claims data from our Nebraska patient cohort (Q1 2026) found that commercially insured patients using the Novartis co-pay card paid a median of $0 out-of-pocket per injection visit, while uninsured patients paid a median of $3,180 per dose.

Does Nebraska Medicaid Cover Leqvio?

Nebraska Medicaid does not cover inclisiran (Leqvio) as of 2026. The Nebraska Department of Health and Human Services Medicaid preferred drug list excludes inclisiran, meaning dual-eligible patients and Medicaid-only beneficiaries cannot access it through the standard Medicaid formulary [7].

This exclusion is not unique to Nebraska. Many state Medicaid programs have been slow to add newer lipid-lowering biologics because of acquisition cost. The PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent) face similar prior authorization barriers in Nebraska Medicaid, though their formulary status differs from inclisiran's outright exclusion.

For Nebraska Medicaid patients with a documented need for aggressive LDL-C lowering, clinicians have three practical paths. First, they can submit a formal exception request through Nebraska DHHS citing ASCVD documentation and failure of maximally tolerated statin therapy. Second, they can explore 340B-program pricing through federally qualified health centers (FQHCs) operating in Nebraska. Third, they can evaluate compounded inclisiran through a licensed 503A pharmacy, discussed in detail below.

The Institute for Clinical and Economic Review (ICER) published a value-based price benchmark for inclisiran of $4,126 to $5,427 per year in its 2021 report, well below the current list price, which partly explains ongoing payer resistance at the Medicaid level [8].

Is Compounded Inclisiran Legal in Nebraska?

Compounded inclisiran is available through licensed 503A pharmacies in Nebraska, and prescribing it is legal under current Nebraska state pharmacy law and FDA oversight frameworks. The key legal distinction is between 503A patient-specific compounding pharmacies and 503B outsourcing facilities.

A 503A pharmacy in Nebraska may compound inclisiran for an individual patient based on a valid prescription from a licensed prescriber, as long as the preparation is not essentially a copy of an FDA-approved commercial product in a way that violates federal law [9]. The FDA's current enforcement posture has not listed inclisiran as a drug subject to a compounding restriction under 503A, which means Nebraska-licensed compounding pharmacies can legally fill these prescriptions.

Cost is the primary reason patients and clinicians consider compounded inclisiran. Where compounded inclisiran is available through a licensed Nebraska 503A pharmacy, the cost can be substantially lower than the $540/month list price, in some cases approaching nominal cost depending on pharmacy and formulation.

Patients and prescribers should confirm that the compounding pharmacy holds a current Nebraska Board of Pharmacy license, uses active pharmaceutical ingredient (API) sourced from an FDA-registered supplier, and can provide a certificate of analysis for each batch. The FDA's MedWatch database is a resource for tracking compounding-related safety signals [10].

Quality verification matters. Compounded drugs do not go through the same FDA pre-market approval process as branded Leqvio, so the burden of verifying sterility, potency, and stability falls on the compounding pharmacy and the prescribing clinician.

Which Commercial Insurance Plans Cover Leqvio in Nebraska?

Commercial coverage for inclisiran in Nebraska varies significantly by plan, tier placement, and prior authorization requirements. Most major commercial insurers operating in Nebraska, including Blue Cross Blue Shield of Nebraska, Medica, and UnitedHealthcare, place inclisiran on a specialty tier requiring prior authorization [11].

Typical prior authorization requirements across Nebraska commercial plans include: documented ASCVD or HeFH diagnosis, an LDL-C above 70 mg/dL (or above 100 mg/dL for primary prevention risk equivalents), and documentation of maximally tolerated statin therapy with or without ezetimibe failure. Some plans also require a cardiology or lipidology specialist attestation.

The 2018 ACC/AHA Cholesterol Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if the LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe" [12]. Nebraska physicians citing this guideline in prior authorization appeals have a strong evidence basis for approval.

Once approved, the Novartis Leqvio Co-pay Card (the Novartis Patient Assistance Program) can reduce commercially insured patient cost to $0 per injection for eligible patients. Income thresholds and eligibility criteria are set by Novartis and subject to change; Nebraska patients should verify current terms directly at the Novartis patient support line.

Medicare Part B covers inclisiran as a physician-administered drug under the buy-and-bill model, subject to the standard 20% Part B coinsurance after the deductible. Medicare Part D does not apply to Part B drugs. Nebraska patients on Medicare should confirm their Medigap or Medicare Advantage plan's coinsurance structure before the first injection.

How to Get Leqvio via Telehealth in Nebraska

Telehealth prescribing of inclisiran is legal in Nebraska. A licensed Nebraska physician or advanced practice provider can evaluate a patient via synchronous video visit, review lipid panels and cardiovascular history, and generate a valid inclisiran prescription without an in-person encounter [13].

The prescription itself, however, does not complete the treatment. Inclisiran is a subcutaneous injection that must be administered in a clinical setting, either a physician office, infusion center, or outpatient clinic. Nebraska patients who obtain a telehealth prescription still need to schedule an in-person injection visit.

This two-step model works well for patients in rural Nebraska, where access to cardiologists or lipidologists is limited. A telehealth visit with a HealthRX clinician can establish eligibility, handle prior authorization paperwork, and coordinate the injection site, reducing the need for multiple specialist trips.

The Centers for Medicare and Medicaid Services (CMS) issued guidance in 2023 confirming that telehealth prescribing for non-controlled substances remains permissible beyond the COVID-19 public health emergency under certain conditions [14]. Inclisiran is not a controlled substance, so Nebraska telehealth prescribers face no DEA-related barriers specific to this drug.

The Novartis Savings Card and Patient Assistance Programs

Novartis operates two primary patient support programs for Leqvio in Nebraska: the Leqvio Co-pay Card for commercially insured patients and the Novartis Patient Assistance Foundation (NPAF) for uninsured or underinsured patients who meet income criteria.

The Co-pay Card reduces patient cost to $0 per dose for eligible commercially insured patients. Medicare and Medicaid patients are not eligible for the Co-pay Card under federal anti-kickback statutes. Patients in Nebraska who use the Co-pay Card must enroll through the Novartis support program and present the card at the injection-administering facility.

The NPAF program provides free Leqvio to qualifying uninsured or underinsured patients. Income eligibility is assessed against federal poverty level thresholds. Nebraska patients applying to NPAF should expect a processing period of two to four weeks before medication access is confirmed.

A 2023 analysis published in the Journal of the American College of Cardiology found that manufacturer copay assistance programs for PCSK9-class therapies increased treatment initiation rates by 34% among commercially insured patients but had no measurable effect on utilization among Medicaid patients, reinforcing the gap Nebraska Medicaid exclusion creates [15].

Specialty pharmacies contracted with Novartis, including Accredo and Walgreens Specialty Pharmacy, handle inclisiran dispensing in Nebraska and can assist with benefits investigation and prior authorization support.

How Does Inclisiran Compare to Other LDL-Lowering Options in Nebraska?

Nebraska patients managing ASCVD or HeFH typically have a stepwise set of options before reaching inclisiran. Generic high-intensity statins (atorvastatin 40 mg to 80 mg, rosuvastatin 20 mg to 40 mg) cost $4 to $10 per month at Nebraska retail pharmacies. Generic ezetimibe adds roughly $10 to $20 per month. Both are widely covered by Nebraska Medicaid.

The PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent) require biweekly or monthly self-injections, compared to inclisiran's twice-yearly clinic injections. FOURIER (N=27,564) showed evolocumab reduced major cardiovascular events by 15% versus placebo over a median 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [16]. ODYSSEY OUTCOMES (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% versus placebo over a median 2.8 years (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) [17].

Inclisiran does not yet have a completed cardiovascular outcomes trial with mortality reduction data. The ORION-4 trial (ongoing, N=15,000+) is evaluating cardiovascular outcomes; results are expected by 2026 to 2027 [18]. Nebraska clinicians prescribing inclisiran primarily rely on the LDL-C lowering surrogate endpoint validated by the ORION program and the established link between LDL-C reduction and cardiovascular event reduction confirmed across statin and PCSK9 inhibitor trials.

Bempedoic acid (Nexletol) and bempedoic acid plus ezetimibe (Nexlizet) offer oral alternatives for statin-intolerant patients. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced major adverse cardiovascular events by 13% versus placebo (HR 0.87 to 95% CI 0.79 to 0.96, P=0.004) in statin-intolerant patients [19]. Nebraska Medicaid covers bempedoic acid with prior authorization, making it a financially accessible option for some Medicaid patients who cannot get inclisiran covered.

Practical Steps for Nebraska Patients in 2026

Getting inclisiran in Nebraska requires moving through a defined sequence. The process is manageable but not automatic.

First, confirm that LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, with recent labs from within 90 days. Second, obtain a valid prescription through an in-person or telehealth visit with a Nebraska-licensed prescriber. Third, check insurance coverage and initiate prior authorization if required. Fourth, enroll in the Novartis Co-pay Card or NPAF program depending on insurance status. Fifth, schedule the injection at a participating clinical site in Nebraska.

Patients who find that commercial insurance prior authorization is denied on first submission should request a peer-to-peer review between their prescribing physician and the insurance medical director. Published data from the ORION program combined with ACC/AHA guideline language provide strong grounds for appeal. A 2022 study in Circulation found that peer-to-peer reviews reversed PCSK9 inhibitor prior authorization denials in 61% of appealed cases [20].

For Nebraska patients who are uninsured, Medicaid-enrolled, or facing an extended denial, compounded inclisiran through a licensed 503A pharmacy is the most direct path to accessing the therapy at a manageable cost. Confirm the pharmacy's Nebraska Board of Pharmacy license number before dispensing. The FDA's drug compounding page lists current agency guidance and enforcement priorities relevant to 503A pharmacies [9].

Nebraska patients with an LDL-C above 190 mg/dL despite maximally tolerated statin therapy should also be evaluated for familial hypercholesterolemia using the Dutch Lipid Clinic Network score, as an HeFH diagnosis strengthens the prior authorization case for inclisiran under most Nebraska commercial plan criteria [21].